For over a century, researchers have attempted to enlist the body's immune system in the battle against cancer. It is, however, only in the last decade that discoveries regarding the molecular process of immune regulation have provided the means for developing immunotherapies to treat a variety of cancers. The competition in this area has, in fact, grown to the point where there are now hundreds of different cancer vaccines in various stages of development.
The CEO of Onyvax Ltd. , Anthony Walker, PhD, is keenly aware of the competition his cancer immunology company...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?